Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors

May 17, 2020 updated by: Ruth E. Patterson, University of California, San Diego

Obesity-related Mechanisms and Mortality in Breast Cancer Survivors

This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle intervention and metformin (a drug used to treat diabetes) to investigate how these treatments, alone or in combination, affect biomarkers associated with breast cancer survival. The Reach for Health Study will enroll 340 overweight/obese, postmenopausal breast cancer survivors. After completing the screening process and baseline measures, participants will be randomized in equal numbers to: (1) placebo, (2) metformin, (3) lifestyle intervention and placebo, or (4) lifestyle intervention and metformin. The intervention was powered on the main effects and the planned analyses are to compare: Metformin to Placebo and a separate comparison of Lifestyle intervention to control. The interventions will last for 6 months. Concentrations of circulating biomarkers will be assessed at baseline and 6 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

333

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • La Jolla, California, United States, 92093
        • Moores UCSD Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • BMI at least 25.0 kg/m2
  • Diagnosed with Stage I, II, or III breast cancer within past 5 years
  • Treatment with total mastectomy or breast-sparing surgical removal of cancer with clear macroscopic margins, and axillary dissection, followed by adjuvant breast radiation
  • Not scheduled for or currently undergoing chemotherapy
  • Accessible geographically and by telephone
  • Able to communicate dietary and physical activity data via telephone
  • If taking statins, tamoxifen, or aromatase inhibitors; able and willing to remain on treatment for 6-month study period
  • Post-menopausal at diagnosis

Exclusion Criteria:

  • Preliminary bloodwork outside of specified ranges
  • Evidence of renal insufficiency, liver disease, or congestive heart failure
  • Currently taking corticosteroid pills or steroid hormone therapy (including vaginal estrogen creams)
  • Recent initiation (< 3 months ago) of thiazides or β-blockers
  • Taking insulin or other antidiabetic drug
  • Other primary or recurrent invasive cancer in past 10 years
  • Unable to commit to study requirements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Metformin + lifestyle intervention
Drug: Metformin
Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Behavioral: Lifestyle intervention
Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
Active Comparator: Placebo + lifestyle intervention
Behavioral: Lifestyle intervention
Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
Drug: Placebo
Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Other Names:
  • Sugar pill
Active Comparator: Metformin + standard dietary guidelines
Drug: Metformin
Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
Behavioral: Standard printed dietary guidelines
Set of standard health education materials provided to participants at single time point (immediately after randomization)
Placebo Comparator: Placebo + standard dietary guidelines
Drug: Placebo
Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
Other Names:
  • Sugar pill
Behavioral: Standard printed dietary guidelines
Set of standard health education materials provided to participants at single time point (immediately after randomization)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insulin
Time Frame: change from baseline to 6 months
Insulin measured as percent change from baseline
change from baseline to 6 months
Glucose
Time Frame: change from baseline to 6 months
Glucose measured as percent change from baseline
change from baseline to 6 months
C-reactive Protein
Time Frame: change from baseline to 6 months
C-reactive protein measured as percent change from baseline
change from baseline to 6 months
Bioavailable Testosterone
Time Frame: change from baseline to 6 months
Bioavailable testosterone measured as percent change from baseline
change from baseline to 6 months
Serum Hormone Binding Globulin
Time Frame: change from baseline to 6 months
Serum hormone binding globulin measured as percent change from baseline
change from baseline to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of California, San Diego

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2011

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

February 23, 2011

First Submitted That Met QC Criteria

February 23, 2011

First Posted (Estimate)

February 24, 2011

Study Record Updates

Last Update Posted (Actual)

June 5, 2020

Last Update Submitted That Met QC Criteria

May 17, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • U54 CA155435-01 Project 3

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Neoplasms

Clinical Trials on Metformin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe